Two/CD Japanese/JJ scientists/NNS said/VBD 0/-NONE- they/PRP discovered/VBD an/DT antibody/NN that/IN ,/, in/IN laboratory/NN test-tube/NN experiments/NNS ,/, *T*-1/-NONE- kills/VBZ AIDS-infected/JJ cells/NNS while/IN *-2/-NONE- preserving/VBG healthy/JJ cells/NNS ./.
If/IN further/JJ experiments/NNS are/VBP successful/JJ ,/, the/DT work/NN would/MD represent/VB a/DT major/JJ advance/NN in/IN research/NN on/IN acquired/VBN immune/JJ deficiency/NN syndrome/NN ./.
The/DT drug/NN AZT/NNP ,/, the/DT only/JJ treatment/NN currently/RB on/IN the/DT market/NN ,/, claims/VBZ *-1/-NONE- only/RB to/TO help/VB *-3/-NONE- stop/VB the/DT spread/NN of/IN AIDS/NNP ,/, not/RB to/TO cure/VB it/PRP ./.
But/CC several/JJ analysts/NNS and/CC Japanese/JJ scientists/NNS familiar/JJ with/IN the/DT study/NN ,/, which/WDT *T*-2/-NONE- was/VBD announced/VBN *-1/-NONE- at/IN a/DT conference/NN in/IN Nagoya/NNP yesterday/NN ,/, expressed/VBD skepticism/NN over/IN the/DT significance/NN of/IN the/DT results/NNS ./.
And/CC the/DT researchers/NNS themselves/PRP acknowledged/VBD 0/-NONE- they/PRP still/RB must/MD do/VB much/RB more/JJR work/NN before/IN they/PRP can/MD say/VB whether/IN the/DT treatment/NN would/MD actually/RB cure/VB humans/NNS ./.
Shin/NNP Yonehara/NNP ,/, a/DT research/NN scientist/NN at/IN the/DT Tokyo/NNP Metropolitan/NNP Institute/NNP of/IN Medical/NNP Science/NNP ,/, said/VBD 0/-NONE- the/DT antibody/NN 0/-NONE- he/PRP discovered/VBD *T*-2/-NONE- works/VBZ by/IN */-NONE- recognizing/VBG an/DT antigen/NN called/VBN */-NONE- a/DT Fas-antigen/NN ,/, which/WDT *T*-1/-NONE- is/VBZ characteristic/JJ of/IN an/DT infected/JJ cell/NN ./.
The/DT antibody/NN then/RB kills/VBZ the/DT cell/NN ./.
Dr./NNP Yonehara/NNP and/CC his/PRP$ partner/NN ,/, Nobuyuki/NNP Kobayashi/NNP of/IN Yamaguchi/NNP University/NNP ,/, said/VBD 0/-NONE- their/PRP$ experiments/NNS showed/VBD that/IN the/DT antibody/NN wiped/VBD out/RP an/DT average/NN of/IN 60/CD %/NN of/IN AIDS-infected/JJ cells/NNS within/IN three/CD days/NNS ./.
In/IN some/DT of/IN the/DT experiments/NNS ,/, it/PRP killed/VBD almost/RB all/PDT the/DT infected/JJ cells/NNS ,/, the/DT researchers/NNS said/VBD 0/-NONE- *T*-1/-NONE- ./.
Meanwhile/RB ,/, fewer/JJR than/IN 10/CD %/NN of/IN the/DT healthy/JJ cells/NNS were/VBD killed/VBN *-1/-NONE- ./.
The/DT two/CD said/VBD 0/-NONE- they/PRP must/MD still/RB do/VB more/JJR laboratory/NN tests/NNS ,/, then/RB experiment/NN on/IN animals/NNS ./.
They/PRP said/VBD 0/-NONE- they/PRP hoped/VBD *-1/-NONE- to/TO conduct/VB tests/NNS on/IN human/JJ patients/NNS in/IN the/DT U.S./NNP by/IN late/JJ next/JJ year/NN ./.
Japan/NNP does/VBZ n't/RB have/VB enough/JJ AIDS/NNP patients/NNS *-1/-NONE- to/TO do/VB significant/JJ experimentation/NN in/IN that/DT country/NN ,/, they/PRP said/VBD 0/-NONE- *T*-2/-NONE- ./.
The/DT announcement/NN got/VBD wide/JJ exposure/NN in/IN the/DT Japanese/JJ media/NNS ,/, and/CC even/RB moved/VBD some/DT pharmaceutical/JJ stocks/NNS yesterday/NN ./.
But/CC Takashi/NNP Kitamura/NNP ,/, director/NN of/IN the/DT biology/NN department/NN at/IN Japan/NNP 's/POS National/NNP Institute/NNP of/IN Health/NNP and/CC secretary/NN of/IN the/DT government/NN 's/POS AIDS-research/JJ center/NN ,/, said/VBD ,/, ``/`` I/PRP 'm/VBP not/RB so/RB optimistic/JJ of/IN its/PRP$ future/JJ use/NN in/IN therapeutic/JJ methods/NNS ./. ''/''
He/PRP said/VBD 0/-NONE- some/DT infected/JJ cells/NNS may/MD not/RB have/VB the/DT relevant/JJ antigen/NN and/CC so/RB would/MD n't/RB be/VB killed/VBN *-1/-NONE- even/RB after/IN exposure/NN to/TO the/DT antibody/NN ./.
``/`` The/DT results/NNS seem/VBP *-1/-NONE- to/TO be/VB very/RB premature/JJ ,/, ''/'' said/VBD *T*-2/-NONE- Mitsuru/NNP Miyata/NNP ,/, editor/NN of/IN Nikkei/NNP Biotechnology/NNP ,/, a/DT leading/VBG Japanese/JJ industry/NN newsletter/NN ./.
Dr./NNP Kobayashi/NNP responded/VBD that/IN he/PRP thought/VBD 0/-NONE- the/DT antibody/NN could/MD potentially/RB kill/VB all/DT infected/JJ cells/NNS ./.
But/CC he/PRP and/CC Dr./NNP Yonehara/NNP said/VBD 0/-NONE- there/EX were/VBD still/RB several/JJ uncertainties/NNS ,/, particularly/RB regarding/VBG possible/JJ side/NN effects/NNS ./.
``/`` Our/PRP$ antibody/NN specifically/RB killed/VBD infected/JJ cells/NNS at/IN a/DT very/RB low/JJ dose/NN ,/, but/CC it/PRP can/MD also/RB kill/VB other/JJ cells/NNS ,/, ''/'' said/VBD *T*-1/-NONE- Dr./NNP Yonehara/NNP ./.
``/`` We/PRP do/VBP n't/RB know/VB the/DT effect/NN of/IN our/PRP$ antibody/NN on/IN the/DT human/JJ body/NN ./. ''/''
AIDS/NNP is/VBZ n't/RB considered/VBN *-1/-NONE- a/DT widespread/JJ problem/NN in/IN Japan/NNP --/: the/DT government/NN reports/VBZ about/IN 1,000/CD known/VBN carriers/NNS of/IN the/DT virus/NN --/: but/CC many/JJ companies/NNS have/VBP poured/VBN substantial/JJ resources/NNS into/IN research/NN in/IN recent/JJ years/NNS ,/, *-2/-NONE- hoping/VBG *-3/-NONE- to/TO cash/VB in/RP on/IN a/DT possible/JJ cure/NN ./.
Dr./NNP Kitamura/NNP said/VBD 0/-NONE- about/IN 35/CD projects/NNS are/VBP currently/RB under/IN way/NN in/IN Japan/NNP ,/, and/CC that/IN Japanese/JJ researchers/NNS in/IN the/DT past/JJ year/NN have/VBP made/VBN available/JJ *ICH*-1/-NONE- *ICH*-2/-NONE- three/CD possible/JJ cures/NNS to/TO American/JJ researchers/NNS for/IN clinical/JJ tests/NNS ./.
He/PRP said/VBD that/IN when/WRB scientists/NNS from/IN the/DT two/CD countries/NNS meet/VBP again/RB in/IN January/NNP in/IN New/NNP Orleans/NNP *T*-1/-NONE- ,/, the/DT Japanese/NNP will/MD present/VB at/IN least/JJS three/CD more/JJR drugs/NNS for/IN human/JJ testing/NN ./.
AZT/NNP is/VBZ the/DT world/NN 's/POS only/JJ prescription/NN medicine/NN approved/VBN */-NONE- for/IN */-NONE- treating/VBG the/DT disease/NN ./.
Wellcome/NNP PLC/NNP ,/, a/DT major/JJ British/JJ pharmaceutical/NN maker/NN ,/, sells/VBZ the/DT drug/NN under/IN the/DT name/NN Retrovir/NNP ./.
A/DT Wellcome/NNP spokesman/NN declined/VBD *-1/-NONE- to/TO comment/VB on/IN the/DT discovery/NN of/IN the/DT antibody/NN in/IN Japan/NNP ./.
But/CC Andrew/NNP Porter/NNP ,/, a/DT drug-industry/NN analyst/NN at/IN Nikko/NNP Securities/NNPS Co./NNP in/IN London/NNP ,/, said/VBD 0/-NONE- if/IN the/DT product/NN were/VBD *-2/-NONE- to/TO be/VB successfully/RB developed/VBN *-1/-NONE- it/PRP would/MD represent/VB ``/`` a/DT potential/JJ threat/NN to/TO the/DT long-term/JJ viability/NN of/IN Retrovir/NNP ./.

